The advent of immune checkpoint inhibitors (ICI) targeting the programmed cell death (ligand) 1 (PD-1) and PD-L1 pathways has improved overall survival (OS) significantly in patients with LR and/or metastatic HNSCC, particularly those with PD-L1-positive tumours [11]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.